4.15 References 總表
指引（Guidelines）
EAU Guidelines on Urological Infections 2025
EAU 2025 PDF Full Guideline
EAU 2025 Summary of Changes
IDSA 2025 Complicated UTI Guideline (Official)
IDSA 2025 cUTI — CID Full Article
IDSA 2025 cUTI — Press Release
AUA/CUA/SUFU 2025 Recurrent UTI Update
AUA 2025 J Urol Article
IDSA 2024 AMR Guidance
IDSA 2022 ESBL-E / CRE / DTR-P Guidance (PMC)
ACOG 2023 UTI in Pregnancy
AAP 2021 Febrile Infants 8–60 Days
IDSA 2019 Asymptomatic Bacteriuria — Official
IDSA 2019 ASB — CID Full Article
AAP 2011 UTI in Children 2–24 Months
IDSA 2010 Uncomplicated Cystitis & Pyelonephritis (Official)
IDSA 2010 — PubMed
IDSA 2009 CAUTI Guideline
Landmark RCTs
ALTAR — Methenamine vs antibiotic for rUTI (BMJ 2022)
ImpresU — Methenamine in older women (CMI 2025)
Drekonja DM et al., 7 vs 14 days for men with UTI (JAMA 2021)
GSK Blujepa (gepotidacin) FDA Approval Press Release
BLUJEPA FDA Label (PDF)
台灣藥物與感控資源
食藥署西藥許可證查詢
中央健保署藥品代碼查詢
台灣感染症醫學會
疾病管制署 抗生素抗藥性監測
⚠️ 免責聲明：本整理為臨床知識複習用途，實際處方需依個別病人狀況、共病、藥物交互作用、健保給付狀態、本院 antibiogram 與最新指引調整，並由醫師判斷。商品名與健保給付以衛福部食藥署許可證與健保署公告為準。
